Back to collectionInjective and BDACS Plan KRW1 Settlement for Tokenized Assets
A memorandum sets out a path for KRW1 to become a won-denominated settlement asset on Injective, but minting, redemption and specific markets remain subject to approval and later implementation.
Injective and Korean custodian BDACS signed a memorandum of understanding to explore using KRW1 as a won-denominated settlement asset for tokenized real-world assets on Injective. Injective’s 20 October announcement says KRW1 is issued by BDACS and backed one-for-one by Korean won. Minting and redemption are intended for approved institutional partners and remain subject to regulatory approval.
The useful change is a defined institutional settlement plan, not a completed market launch. The parties say they will work with Korean financial institutions and develop won-settled use cases, but the announcement does not identify live trading pairs, completed integrations or transaction volume. Those implementation milestones require later evidence.